Middle East And Africa Neurodegenerative Disease Market Size, Share & Trends Analysis Report By Disease Indication (Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, Others), By Drug Type (Immunomodulator, Vesicular Monoamine Transporter 2 (VMAT2), Others), By Routes of Administration (Oral, Intravenous (IV) delivery, Others) and By Country (UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Rest of MEA) Forecasts, 2026-2034

Market Overview

The middle east and africa neurodegenerative disease market size was valued at USD 3.96 billion in 2025 and is projected to grow from USD 4.27 billion in 2026 to reach USD 7.85 billion by 2034, growing at a CAGR of 7.9% during the forecast period 2026–2034.

In most cases, neurodegenerative disorders are characterized by gradual nerve cell degeneration that can occur in a variety of locations across the body. Loss of memory and cognitive control are potential outcomes of a number of conditions, including Alzheimer's disease, Parkinson's disease, attention deficit hyperactivity disorder (ADHD), and amyotrophic lateral sclerosis (ALS).

Although there are very few diseases that can be cured, the pharmaceutical industry has developed a variety of treatments throughout the years that aim to alleviate the symptoms of neurodegenerative ailments.

Neurodegenerative disorders are a varied group of ailments defined by the gradual degradation of the function and structure of the central nervous system or peripheral nervous system. Neurodegenerative disorders, including Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, and Huntington's disease, have been rising globally. Thus, the growing burden of this condition is the key driver driving the market expansion, adding to it the expanding elderly population. According to NIH, nearly 1.2 million people in the United States will have Parkinson's disease by 2030. In the United States, it is the second most frequent neurodegenerative disorder.

Furthermore, according to Alzheimer's Disease International, more than 50 million adults with dementia globally in 2020. This number is anticipated to be more than double every two decades, reaching 82 million in 2030 and 152 million in 2050. Additionally, much of the increase will be in emerging countries. About 60% of persons with dementia reside in poor and middle-income nations, but by 2050, this will climb to 71%. The fastest rise in the senior population has happened in China, India, and South Asian and western Pacific countries. Thus, the growing burden of dementia is likely to enhance the market growth in the approaching years.

Market Dynamics

Drivers

Neurological disorders are characterized largely by their symptoms, and there are currently no treatment options that may cure these conditions. The major objective of treating neurodegenerative diseases is to maintain control over the signs and symptoms of the condition, which might include tremors in the hands, difficulty walking, and a general slowing of movement. The treatment plan for each individual is tailor-made to address their specific symptoms.

In the Middle East and Africa area, an expansion of the treatment market for neurodegenerative diseases is anticipated due to the rising prevalence of environmental factors and genetic inheritance. In addition, recent developments in the treatment of neurodegenerative diseases, such as combination therapies to extend the action of continuous dopaminergic stimulation drugs, approval for neurostimulation devices, neuroprotective therapies to slow disease progression, gene therapy, neural transplantation, and other developments, are anticipated to drive massive growth in the Middle East and Africa market for neurological disease treatments.

A year-over-year increase in the elderly population, which is anticipated to be aided by the rising prevalence of Parkinson's disease and another neurological disease, and which is anticipated to accelerate the market's growth rate during the forecast period in this region is expected to be one of the primary factors driving the market. Increasing investments in research & development lead to the creation of innovative therapies, which in turn is anticipated to assist in the growth of the market. As more individuals become aware of the many treatment options available, there will be a greater demand for treatment of Parkinson's disease.

Additionally, factors such as rising breakthroughs in the manufacturing of novel medicines and improving health infrastructure in various MEA nations are projected to drive market expansion in the future years. This is predicted to be the case since these variables are expected to play a role. In addition, increasing consumer demand for services of a higher quality, which is driving higher healthcare spending, is projected to lead to further market expansion.

Restraints

Parkinson's disease is a neurodegenerative disorder that primarily impacts the human brain. This condition makes it difficult to operate and to carry out the activities of daily living. Parkinson's disease is characterised by a lack of dopamine production, which leads in a variety of symptoms, including stiffness, tremors, and trouble walking. This ailment has the potential to become fairly dangerous if it is not treated as soon as it is detected.

However, effective symptomatic treatment for Parkinson's disease is no longer accessible because of the pandemic's limitations on available resources and its diversion of those resources.

Middle East And Africa Neurodegenerative Disease Market Segmental Analysis

By Disease Indication

The Middle East and Africa neurodegenerative disease market is segmented by disease indication into multiple sclerosis, Parkinson's disease, Alzheimer's disease, and others. Multiple sclerosis requires prolonged medical supervision and continued therapeutic management, creating demand for disease-modifying and supportive treatment options. Parkinson's disease is also becoming increasingly important as improvements in life expectancy and healthcare access contribute to greater recognition of age-related neurological disorders. Alzheimer's disease represents another significant indication, particularly as awareness of dementia and cognitive decline increases among patients, families, and healthcare professionals. Improvements in neurological diagnostics and the gradual expansion of specialist services are supporting the identification and management of these conditions across the region.

The others category includes a broad range of neurodegenerative and neurological disorders that require specialized diagnosis and treatment. Greater awareness of neurological symptoms, expansion of healthcare facilities, and improvements in diagnostic capabilities are helping healthcare providers identify conditions that may previously have been underdiagnosed. The market across the Middle East and Africa is also supported by increasing healthcare investments, development of specialist hospitals, and growing demand for long-term disease management. However, differences in healthcare infrastructure, treatment affordability, availability of neurologists, reimbursement systems, and access to advanced medicines remain important factors affecting treatment adoption across individual countries.

Request Customizationto receive a tailored report.

By Drug Type

The Middle East and Africa neurodegenerative disease market is classified by drug type into immunomodulator, vesicular monoamine transporter 2 (VMAT2), and others. Immunomodulators are relevant to neurological conditions in which immune-system activity contributes to disease mechanisms, creating demand for therapies that can influence abnormal immune responses. VMAT2 represents a specialized drug category associated with the regulation of neurotransmitter activity and the management of certain movement-related neurological symptoms. Increasing awareness of advanced neurological treatments and improvements in specialist healthcare are gradually supporting the adoption of these therapies. Countries with stronger healthcare infrastructure and greater access to specialized medicines are expected to remain important contributors to the segment.

The others segment includes drug therapies that operate through mechanisms outside immunomodulation and VMAT2 targeting. These medicines can be used for symptom control, disease management, or addressing specific neurological pathways depending on the patient's condition. Pharmaceutical research and the introduction of therapies with new mechanisms of action could expand treatment options across the region. Market development is influenced by medicine availability, regulatory approvals, treatment costs, physician awareness, reimbursement policies, and access to specialist care. As healthcare systems across the Middle East and Africa continue to develop, wider availability of neurological medicines is expected to support gradual growth in this segment.

By Routes of Administration

The Middle East and Africa neurodegenerative disease market is segmented by routes of administration into oral, intravenous (IV) delivery, and others. Oral administration remains a widely relevant treatment route because tablets and capsules are convenient for patients requiring long-term medication and can often be administered without specialized medical supervision. This route supports outpatient treatment and can reduce the frequency of healthcare-facility visits. Intravenous (IV) delivery is used when a therapy requires direct bloodstream administration, controlled dosing, or monitoring by healthcare professionals. Improvements in hospitals, specialty clinics, and neurological treatment centers are supporting the availability of IV-based therapies in countries with more developed healthcare systems.

The others category covers alternative administration methods that may be appropriate when oral or IV delivery does not provide the desired therapeutic or practical benefits. Advances in drug formulation and delivery technologies are creating opportunities for treatment approaches designed to improve drug absorption, maintain consistent therapeutic exposure, or increase patient convenience. The selection of administration route depends on the drug's characteristics, disease severity, patient requirements, and clinical considerations. Across the Middle East and Africa, adoption of different delivery methods will continue to be influenced by healthcare infrastructure, treatment affordability, regulatory requirements, availability of trained professionals, and access to specialized neurological therapies.

Speak to an Analystto discuss market opportunities.

Regional Analysis

In terms of geography, it is anticipated that the regional markets of the Middle East and Africa would account for a moderate proportion of the worldwide market over the period covered by the projection. The increasing burden of neurological illness management of the healthcare systems of big countries, such as the UAE and Kuwait, would motivate the government to undertake aggressive efforts to speed research and development in the treatment of neurodegenerative diseases.

List of Key and Emerging Players in Middle East And Africa Neurodegenerative Disease Market

• Abbvie Inc
• Amneal Pharmaceuticals Inc.
• Boehringer Ingelheim International GmbHF
• Hoffmann-La Roche
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceuticals Ltd
• UCB SA
• Biogen Inc